| (Values in U.S. Thousands) | Jun, 2021 | Jun, 2020 | Jun, 2019 | Jun, 2018 | Jun, 2017 |
| Sales | 74,020 | 62,480 | 38,850 | 36,670 | 27,260 |
| Sales Growth | +18.47% | +60.82% | +5.94% | +34.52% | +17.96% |
| Net Income | -14,470 | -17,420 | -7,390 | -7,610 | -1,680 |
| Net Income Growth | +16.93% | -135.72% | +2.89% | -352.98% | -43.59% |
Misonix Inc (MSON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Misonix, Inc. designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Misonix acquired worldwide rights to use the Focus technology in kidney, liver and breast treatment. Addressing a combined market estimated to be in excess of $four billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.
Fiscal Year End Date: 06/30